Stock Analysis

Do Institutions Own Shares In Creo Medical Limited (LON:CREO)?

A look at the shareholders of Creo Medical Limited (LON:CREO) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

With a market capitalization of UK£197m, Creo Medical is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Creo Medical.

View our latest analysis for Creo Medical

AIM:CREO Ownership Summary, March 17th 2020
AIM:CREO Ownership Summary, March 17th 2020

What Does The Institutional Ownership Tell Us About Creo Medical?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Creo Medical already has institutions on the share registry. Indeed, they own 72% of the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Creo Medical's historic earnings and revenue, below, but keep in mind there's always more to the story.

AIM:CREO Income Statement, March 17th 2020
AIM:CREO Income Statement, March 17th 2020

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Creo Medical. Looking at our data, we can see that the largest shareholder is Hargreave Hale Limited, Asset Management Arm with 14% of shares outstanding. With 8.4% and 8.1% of the shares outstanding respectively, Baillie Gifford & Co. and Development Bank of Wales Plc are the second and third largest shareholders.

On further inspection, we found that 52% of the share register is owned by the top 9 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Creo Medical

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

I can report that insiders do own shares in Creo Medical Limited. In their own names, insiders own UK£7.0m worth of stock in the UK£197m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 13% ownership, the general public have some degree of sway over CREO. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 8.1% stake in CREO. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

It appears to us that public companies own 3.0% of CREO. It's hard to say for sure, but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Creo Medical is showing 5 warning signs in our investment analysis , and 2 of those are significant...

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About AIM:CREO

Creo Medical Group

Through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom.

Adequate balance sheet with low risk.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4036.0% undervalued
32 users have followed this narrative
7 users have commented on this narrative
10 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6090.5% undervalued
30 users have followed this narrative
3 users have commented on this narrative
20 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8151.6% undervalued
49 users have followed this narrative
4 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

AG
Agricola
SRL logo
Agricola on Scully Royalty ·

A case for USD $14.81 per share based on book value. Be warned, this is a micro-cap dependent on a single mine.

Fair Value:US$14.8156.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
OXY logo
composite32 on Occidental Petroleum ·

Occidental Petroleum to Become Fairly Priced at $68.29 According to Future Projections

Fair Value:US$68.2943.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
AGFB logo
RecMag on Agfa-Gevaert ·

Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.

Fair Value:€5.3991.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
122 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8686.1% undervalued
81 users have followed this narrative
8 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.0% undervalued
972 users have followed this narrative
6 users have commented on this narrative
26 users have liked this narrative